Loading clinical trials...
Loading clinical trials...
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% o...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astex Pharmaceuticals, Inc.
NCT06462469 · Steroid-refractory Acute Graft Versus Host Disease
NCT05443425 · Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
NCT06904599 · Acute Graft Versus Host Disease
NCT03057054 · Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, and more
NCT04745637 · Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), and more
MD Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions